ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Hikma Pharmaceuticals USA INC.

Official 2024 U.S. DOL Form 5500 summary for Hikma Pharmaceuticals USA INC. (Hikma Pharmaceuticals USA INC. 401(k) Retirement Plan · EIN 22-3114571 · PN 002): $274.80M net assets, 2,237 active participants, and $9.50 per $10,000 (9.50 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorHikma Pharmaceuticals USA INC.
Filing IdentifierHikma Pharmaceuticals USA INC. 401(k) Retirement Plan · EIN 22-3114571 · PN 002
Plan Category & State401(k) Defined Contribution (NJ)
Asset-Size Peer Cohort$100M-$500M
Plan Net Assets (2024)$274.80M
Active Participants2,237
Direct Admin Fee Rate$9.50 per $10,000 (9.50 bps)
Cohort Peer Median$9.75 per $10,000 (9.75 bps)
Primary Recordkeeper / ProviderBank of America / Merrill
Schedule H Line 4a RemittanceSchedule H Line 4a Late Remittance Reported ($1.15M, often administrative timing)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI

Cross-Agency Entity Graph

Related Filings Across Meru Platforms

Verified federal filings reconciled for Hikma Pharmaceuticals across sibling Meru AI platforms.